Evidence map›Paper›PMID 40144882›Full record

ArticleFrontiers in medicine2025

Predictive value of circulating PD-1

Zhenyu Liu, Wei Zhu, Wentao Yu, Yu Zhou, Xiaojing Dai, Yan Wang, Jingxuan Yu, Lin Wang, Yanbin Niu, Ling Yang and 5 more

Abstract read
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhenyu Liu *Department of Urology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, Hubei, China.
Wei Zhu *Department of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Wentao Yu *Department of Urology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, Hubei, China.
Yu ZhouDepartment of Urology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, Hubei, China.
Xiaojing DaiPostdoctoral Research Workstation, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, Hubei, China.
Yan WangDepartment of Urology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, Hubei, China.
Jingxuan YuDepartment of Urology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, Hubei, China.
Lin WangDepartment of Urology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, Hubei, China.
Yanbin NiuDepartment of Urology, The 985th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Taiyuan, Shanxi, China.
Ling YangDepartment of Urology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, Hubei, China.
Sen XieDepartment of Urology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, Hubei, China.
Ping LongDepartment of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Guohua ZengDepartment of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Lei GaoDepartment of Urology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, Hubei, China.
Tiejun PanDepartment of Urology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, Hubei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The principal objective of this study was to investigate the potential risk factors contributing to the development of postoperative systemic inflammatory response syndrome (SIRS) after percutaneous nephrolithotomy (PCNL), with a key focus on a novel subpopulation of PD-1 Methods: A comprehensive retrospective analysis was undertaken on 399 patients with kidney stones who underwent PCNL at two hospitals between January 2022 and December 2023. The core outcome of interest was the occurrence of post-PCNL SIRS. Univariate and multivariate logistic regression analysis were performed to elucidate independent risk factors for post-PCNL SIRS. A precise nomogram was constructed, integrating the independent risk factors, including Tph cell levels, and receiver operating characteristic (ROC) curves and calibration curves were generated. Results: Among the patients, 142 (35.59%) developed post-PCNL SIRS. Univariate analysis highlighted eight potential risk factors. Notably, multivariate analysis identified five independent risk factors for post-PCNL SIRS: high stone density (odds ratio [OR], 5.96; Conclusion: Patients presenting with low circulating Tph cell levels, high stone density, prolonged operation time, absence of hydronephrosis, and positive urine bacteria are at an elevated risk of developing post-PCNL SIRS. For these individuals, careful consideration of preoperative evaluations, heightened vigilance, and appropriate treatment strategies are essential.

Indexed as

kidney stonenephrolithiasispercutaneous nephrolithotomyperipheral T helper cell (Tph)systemic inflammatory response syndrome

Identifiers

PMID40144882
PMCPMC11936878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.